Flow Pharma (United States)

Recent papers from Flow Pharma (United States)

1. Social support and cognitive function in postmenopausal womenMenopause The Journal of The North American Menopause Society · 2026
2. Antibacterial resistance in dermatology: a modern perspective on the problem and the place of amoxicillin/clavulanic acid in the treatment of bacterial skin infectionsRussian Journal of Clinical Dermatology and Venereology · 2026
3. Feasibility, accuracy, and effect of a rapid point-of-care serological test (SeroSelectTB) to identify presumptive pulmonary TB patients for confirmatory testing in Ethiopia, South Africa, and Tanzania: a multicenter, open-label, parallel-group, randomized, controlled trialEClinicalMedicine · 2026
4. Zwitterionic Mn(III)‐Tetraphenyl Porphyrins: Water‐Soluble MRI Contrast Agents with High RelaxivityChemMedChem · 2026
5. EOSC-ENTRUST D11.1 Provider adoption and evaluation report of Year 2 blueprint and technology, including barriers to adoption & EOSC readiness of the TRE providers with recommendations2026
6. Towards Mechanistic QSAR Approaches for Predicting Reactive Oxygen Species (ROS) Generation: Mini ReviewJournal of Applied Toxicology · 2026
7. The Impact of Psychological Distress on Cognitive Function in Postmenopausal WomenJournal of Women s Health · 2025
8. Keep ’em in the river! Reconsider irrigation water diversion policies to avoid salmon deathsFisheries · 2025
9. Constraining lens masses in moderately to highly magnified microlensing events from GaiaAstronomy and Astrophysics · 2025
10. A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancerCell Reports Medicine · 2025
11. Risk-based in silico mutagenic assessment of benzodiazepine impurities using three QSAR toolsToxicology Reports · 2025
12. Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical TrialDrugs · 2024
13. Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma.Journal of Clinical Oncology · 2024
14. Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC) resistant to second-generation ALK inhibitors.Journal of Clinical Oncology · 2024
15. New Vaccine Therapy for Triple-Negative Breast CancerCurrent Breast Cancer Reports · 2024
16. Neonatal blood pressure by birth weight, gestational age, and postnatal age: a systematic reviewMaternal Health Neonatology and Perinatology · 2024
17. Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle VaccineVaccines · 2024
18. Integrative HLA typing of tumor and adjacent normal tissue can reveal insights into the tumor immune responseBMC Medical Genomics · 2024
19. A redox-based characterization of human immune cell subsets by polychromatic flow cytometrySTAR Protocols · 2023
20. Mindful but forgetful: The negative effect of trait mindfulness on memories of immoral behaviorBusiness and Society Review · 2023